Ba Dinh

This research aims to compare a six-month treatment plan using higher doses of rifampicin, isoniazid, linezolid, and pyrazinamide with the World Health Organizations standard nine-month treatment for tuberculous meningitis TBM in adults and adolescents. Tuberculous meningitis is a serious condition with high risk of death and severe neurological problems. This Phase II, randomized, open-label trial seeks to evaluate if the shorter high-dose regimen can improve functional outcomes compared to the standard care.